ArticleNature2019
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05867004 (Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma), which is not on this map. Cited by 297 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
Who cites it
297 citing papers in PubMed, 2 syntheses or guidelines pooled it, 472 citations in OpenAlex.
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis.Frontiers in immunology · 2024Pooled it
- TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study.International journal of cancer · 2025Trial
- Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- TNFα-driven epigenetic upregulation of TIGIT creates a targetable vulnerability in tumors.Oncogene · 2026Article
- TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.The Journal of experimental medicine · 2026Article
- Anti-PD-1 Therapy and Long-Term Toxic Effects Among Patients With Melanoma.JAMA network open · 2026Article
- Review
- Macrophage-CD8medRxiv : the preprint server for health sciences · 2026Article
- Food-Derived Limosilactobacillus fermentum GR-3 Enhances Anti-PD-1 Immunotherapy Efficacy.Probiotics and antimicrobial proteins · 2026Article
- Tumor microenvironment and signaling pathways in melanoma brain metastasis.Annals of translational medicine · 2026Review
- Article
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
- Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy.Nature reviews. Immunology · 2026Review
- Review
- Targeting MLCK1 uncouples immune checkpoint inhibitor-induced colitis from antitumour immunity.Gut · 2026Article
- Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T cell-derived TNF and TNFR2 signaling.The Journal of experimental medicine · 2026Article
- CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-off.Nature cancer · 2026Article
237 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung cancer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.